BioWorld

Dec. 11, 2009

Cytokinetics Is All Muscle: Ends Cancer Deal with GSK

A year after GlaxoSmithKline plc backed away from two cancer drugs covered under its collaboration with Cytokinetics Inc., the big pharma handed back rights to the third and final compound as well. (BioWorld Today) Read More

New Trial a Show of Confidence for Oncothyreon Cancer Vaccine

Plaques, Bad Cholesterol Get Partial Rehab in Alzheimer's

Despite Concerns, Panel Backs Gilead Inhaled Aztreonam in CF

Financings Roundup

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 20, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...